MA44907A - Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation - Google Patents

Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation

Info

Publication number
MA44907A
MA44907A MA044907A MA44907A MA44907A MA 44907 A MA44907 A MA 44907A MA 044907 A MA044907 A MA 044907A MA 44907 A MA44907 A MA 44907A MA 44907 A MA44907 A MA 44907A
Authority
MA
Morocco
Prior art keywords
methods
host cells
genetically modified
modified host
complex
Prior art date
Application number
MA044907A
Other languages
English (en)
Inventor
Marc Van Dijk
Robert Benjamin Stein
Seibert Volker
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MA44907A publication Critical patent/MA44907A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

La présente invention concerne des cellules hôtes manipulées appropriées pour l'expression de récepteurs de cellules t fonctionnels (tcr) et des procédés d'utilisation de ces cellules pour identifier des tcr qui se lient spécifiquement à un complexe peptide-complexe d'histocompatibilité majeur (mhc) souhaité.
MA044907A 2015-09-11 2016-09-09 Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation MA44907A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562217677P 2015-09-11 2015-09-11

Publications (1)

Publication Number Publication Date
MA44907A true MA44907A (fr) 2018-07-18

Family

ID=56985684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044907A MA44907A (fr) 2015-09-11 2016-09-09 Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation

Country Status (11)

Country Link
US (1) US11898165B2 (fr)
EP (1) EP3347453A1 (fr)
JP (1) JP2018531593A (fr)
KR (1) KR20180043840A (fr)
CN (1) CN108350430A (fr)
AU (1) AU2016318961A1 (fr)
CA (1) CA2996887A1 (fr)
HK (1) HK1256944A1 (fr)
MA (1) MA44907A (fr)
TW (1) TW201716578A (fr)
WO (1) WO2017044672A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
DK2831109T3 (en) 2012-03-28 2018-02-12 Gadeta B V COMBINATORY GAMMA-9-DELTA-2-T-CELL RECEPTOR CHAIN EXCHANGE
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
ES2987986T3 (es) 2016-06-10 2024-11-18 Gadeta B V Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
SG11201909290TA (en) 2017-04-07 2019-11-28 Uti Lp Assay to measure the potency of receptor-ligand interactions in nanomedicines
CA3061614A1 (fr) 2017-04-28 2018-11-01 The Regents Of The University Of Colorado, A Body Corporate Methodes de traitement de la polyarthrite rhumatoide par edition genomique guidee par l'arn d'un gene hla
AU2018268087B2 (en) 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019046856A1 (fr) * 2017-09-04 2019-03-07 Agenus Inc. Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers
TWI814745B (zh) * 2017-10-10 2023-09-11 國立大學法人廣島大學 使用效應T細胞(Teff)抗原受體之抗原特異性控制性T細胞(Treg)之製出技術
CN117820491A (zh) 2017-10-10 2024-04-05 国立大学法人广岛大学 使用铂talen的t细胞受体的完全取代技术
EP3716949A4 (fr) 2017-11-29 2022-05-18 UTI Limited Partnership Méthodes de traitement d'une maladie auto-immune
WO2019238939A1 (fr) * 2018-06-15 2019-12-19 F. Hoffmann-La Roche Ag Système d'identification d'antigènes reconnus par des récepteurs de lymphocytes t exprimés sur des lymphocytes infiltrant les tumeurs
CN109293779A (zh) * 2018-07-03 2019-02-01 清华大学 一种多聚体复合物及其制备方法
MA53505A (fr) * 2018-08-31 2021-12-08 3T Biosciences Inc Bibliothèques peptidiques aléatoires présentées par des antigènes leucocytaires humains
MX2021013218A (es) * 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
EP3808765A1 (fr) 2019-10-14 2021-04-21 ETH Zurich Lignée cellulaire pour la découverte et l'ingénierie tcr et leurs procédés d'utilisation
AU2021297458B2 (en) * 2020-06-25 2026-06-18 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
CN114437232B (zh) * 2020-11-05 2023-11-24 中国科学院分子细胞科学卓越创新中心 一种细胞表面大分子定量展示系统及其制备方法和用途
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US20240060042A1 (en) * 2020-12-22 2024-02-22 National University Of Singapore Artificial antigen-presenting cell
EP4271798A1 (fr) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions et procédés de différenciation de cellules souches en cellules nk
WO2022214707A1 (fr) * 2021-04-09 2022-10-13 Gadeta B.V. Rapporteur cellulaire et ses méthodes d'utilisation
MX2023013438A (es) 2021-05-10 2024-02-29 Univ Colorado Regents Métodos de diseño de hla y composiciones para el tratamiento de la autoinmunidad.
US20240247066A1 (en) * 2021-05-12 2024-07-25 The Board Of Trustees Of The Leland Stanford Junior University Structure based isolation of pmhc-restricted antibodies
US20250152624A1 (en) * 2021-11-02 2025-05-15 Washington University Compositions and methods of treatment for cancers
WO2025045752A1 (fr) * 2023-08-25 2025-03-06 T-Knife Gmbh Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188825A1 (fr) * 2000-09-18 2002-03-20 Universiteit Leiden Tranfert d' un récepteur de cellule T dans une cellule effectrice candidate ou son précurseur
DK1409646T3 (da) * 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
EP3115373B1 (fr) * 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Récepteurs d'antigènes chimériques avec une région de charnière optimisée
WO2013074916A1 (fr) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US9848587B2 (en) * 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice

Also Published As

Publication number Publication date
WO2017044672A1 (fr) 2017-03-16
US20200263133A1 (en) 2020-08-20
AU2016318961A1 (en) 2018-03-22
HK1256944A1 (zh) 2019-10-04
CN108350430A (zh) 2018-07-31
JP2018531593A (ja) 2018-11-01
CA2996887A1 (fr) 2017-03-16
KR20180043840A (ko) 2018-04-30
EP3347453A1 (fr) 2018-07-18
TW201716578A (zh) 2017-05-16
US11898165B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
HK1256944A1 (zh) 经改造的宿主细胞及其使用方法
DK3756682T3 (da) Genetisk modificerede celler, der omfatter et modificeret gen fra det konstante område af den humane t-cellereceptor alpha
MX2018002610A (es) Anticuerpos anti-lag-3.
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
EP3916834A4 (fr) Bloc-batterie
EA202091056A1 (ru) Направленная замена эндогенных т-клеточных рецепторов
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
EP3724321A4 (fr) Lymphocytes car-t immortalisés génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et de la bêta 2-microglobuline
EP3964238A4 (fr) Cellule immunitaire modifiée ciblant bcma et son utilisation
EP3600407C0 (fr) Récepteurs fc améliorés (récepteurs cd3 cd28 fusionnés)
EP2971116A4 (fr) Expression de gène de réponse d'une cellule dendritique, compositions de matières et procédés d'utilisation associés
BR112016024957A2 (pt) métodos aperfeiçoados para fabricação de terapias celulares adotivas
DK3430030T5 (da) Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer
EP3429023A4 (fr) Plateau, ensemble plateau, ensemble bloc-batterie, et véhicule
EP3618144A4 (fr) Composition de liant pour film poreux de batterie secondaire non aqueuse, composition de bouillie pour film poreux de batterie secondaire non aqueuse et film poreux de batterie secondaire non aqueuse, batterie secondaire non aqueuse et son procédé de production
MX2013013832A (es) Proteínas de unión receptoras fc.
EP3464376A4 (fr) Compositions et procédés se rapportant à des constructions fc génétiquement modifiées
EP3849571A4 (fr) Procédés d'expansion de cellules car-t spécifiques d'un antigène, compositions et utilisations associées
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation
EP3365016A4 (fr) Récepteurs de cellules universels programmables et leurs procédés d'utilisation
PL3430037T3 (pl) Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
EP3804741A3 (fr) Procédé de sélection de lymphocytes t génétiquement modifiés
EP3303498A4 (fr) Composition adhésive photo-durcissable, sa préparation et utilisation associée
IL269629A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells